Keywords
dissolution kinetics
analytical method
amoxicillin
How to Cite
Abstract
Introduction
Strengthening the local pharmaceutical industry in the Democratic Republic of the Congo to produce affordable, effective, and high-quality medicines contributes to improved health outcomes and economic development. The government grants a monopoly to local manufacturers for the production of certain generic medicines, such as amoxicillin. These products are required to meet established quality, safety, and efficacy standards to adequately address population health needs.
Purpose
The objective of this study was to evaluate the interchangeability of different brands of amoxicillin produced by local manufacturers in the Democratic Republic of the Congo with a reference (innovator) product through comparative in vitro dissolution testing.
Methods
Two generic products manufactured by local pharmaceutical companies and one innovator product were evaluated. For each product, one batch was randomly purchased from authorised wholesalers. Analyses were conducted using high-performance liquid chromatography in accordance with the United States Pharmacopeia–National Formulary (USP–NF, 2024). Twelve dosage units were analysed to establish dissolution profiles. Comparative dissolution testing was performed at different pH conditions (1.2, 4.5, and 6.8) using a paddle-type dissolution apparatus. Quantification was carried out by UV spectrophotometry, and dissolution profiles were compared using the difference factor (f₁) and similarity factor (f₂). Acceptable ranges were 0–15 for f₁ and 50–100 for f₂.
Results
All samples complied with the USP–NF 2024 specifications. However, dissolution recovery rates differed across sampling points. The fit factor analysis demonstrated interchangeability with the reference product only at pH 1.2, while no similarity was observed at pH 4.5 and 6.8.
Conclusion
The findings indicate potential concerns regarding the efficacy and interchangeability of locally manufactured generic amoxicillin products compared with the innovator product. Manufacturers should re-evaluate their formulations, considering all factors influencing dissolution performance. In addition, regulatory authorities should strengthen post-marketing surveillance to ensure the quality of pharmaceutical products.
References
Abeysinghe, M., et al. (2023). Comparative evaluation of quality of different brands of amoxicillin capsules available in community pharmacies in Jaffna, Sri Lanka. [Journal name not specified].
Akhtar, H., et al. (2023). In vitro assessment and application of kinetics models on dissolution profiles of several brands of clopidogrel (75 mg) available in Karachi, Pakistan. Annals of Jinnah Sindh Medical University, 9(2), 49–55.
Autorité Congolaise de Réglementation Pharmaceutique (ACOREP). (2020, March 5). Décret portant création, organisation et fonctionnement d’un établissement public dénommé Autorité Congolaise de Réglementation Pharmaceutique (ACOREP). https://www.leganet.cd/Legislation/JO/2020/jo.01.04.2020.pdf
Bakker-’t Hart, I. M. E., Ohana, D., & Venhuis, B. J. (2021). Current challenges in the detection and analysis of falsified medicines. Journal of Pharmaceutical and Biomedical Analysis, 197, 113948. https://doi.org/10.1016/j.jpba.2021.113948
Endashaw, E., et al. (2024). Dissolution profile evaluation of selected brands of amoxicillin–clavulanate potassium 625 mg tablets retailed in Hawassa Town, Sidama Regional State, Ethiopia. AAPS Open, 10(1), Article 3. https://doi.org/10.1186/s41120-024-00091-2
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). (2024). ICH M13A: Guideline on bioequivalence for immediate-release solid oral dosage forms.
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). (2025). ICH M13B: Guideline on bioequivalence for immediate-release solid oral dosage forms – Additional strengths biowaiver (Step 2b).
Kalenda Tshilombo, N., et al. (2017). Investigation de la qualité d’antibiotiques à base d’amoxicilline dans le cadre de la surveillance du marché officiel et périphérique de quelques villes de la République démocratique du Congo. In Actes du 12ème Congrès francophone sur les sciences séparatives et les couplages (AFSEP).
Kassaye, L., & Genete, G. (2013). Evaluation and comparison of in vitro dissolution profiles for different brands of amoxicillin capsules. African Health Sciences, 13(2), 369–375.
Kimuntu Kim, P. (2023, October 16). Importante quantité d’antibiotique contrefait Clamoxyl saisie à Lufu, frontière entre la RDC et l’Angola [Post on X]. https://x.com/KimKimuntu/status/1713733638787891467
Mbuya, K. J., et al. (2020). Profil bactériologique des infections urinaires diagnostiquées aux Cliniques Universitaires de Lubumbashi, RDC. IOSR Journal of Dental and Medical Sciences, 19(4), 1–8.
Naing, M. D., & Tsume, Y. (2024). Dissolution profiles of BCS Class II drugs generated by the gastrointestinal simulator alpha have an edge over the compendial USP II method. European Journal of Pharmaceutics and Biopharmaceutics, 203, 114436.
Organisation mondiale de la santé. (2021, May 31). Renforcer la production locale de médicaments et d’autres technologies sanitaires pour en améliorer l’accès. Soixante-quatorzième Assemblée mondiale de la Santé. https://apps.who.int/gb/ebwha/pdf
Organisation mondiale de la santé, Comité régional de l’Afrique. (2024). Cadre pour renforcer la production locale de médicaments, de vaccins et d’autres technologies sanitaires dans la région africaine de l’OMS (2025–2035). https://www.afro.who.int/sites/default/files/2024-09/AFR-RC74-6
Planchon, V. (2022). Réglementation de la publicité en faveur des produits de santé en France (Doctoral thesis). Université de Lille.
United States Pharmacopeial Convention. (2024). USP–NF 2024: General chapter 〈1226〉 Verification of compendial procedures.
Vaikosen, E., et al. (2024). Spectroscopic determination and in vitro bioequivalence studies of different amoxicillin capsule brands. Asian Journal of Research in Biochemistry, 14(3), 26–33. https://doi.org/10.9734/ajrb/2024/v14i3284
VillageReach. (2024, March 6). Améliorer l’accès à des médicaments de qualité grâce à la collaboration entre les secteurs public et privé. https://www.villagereach.org/fr/2024/03/06/ameliorer-lacces-a-des-medicaments-de-qualite-grace-a-la-collaboration-public-prive
Vogler, S., et al. (2021). Policies to encourage the use of biosimilars in European countries and their potential impact on pharmaceutical expenditure. Frontiers in Pharmacology, 12, 625296. https://doi.org/10.3389/fphar.2021.625296
Zoungrana Some, W. (2021). Évaluation in vitro de la bioéquivalence des différentes marques d’amoxicilline gélules commercialisées au Burkina Faso (Master’s thesis). Université Joseph Ki-Zerbo.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.